by Raynovich Rod | Jan 16, 2013 | Biopharmaceuticals, Life Science ETF's and Mutual Funds
A double top in the biotechnology sector could be developing although many mid and small cap stocks are in the green. We are still at or near the October highs in the sector but the seasonality effect is waning (strong November -January performance). Moreover many of...
by Raynovich Rod | Jan 2, 2013 | BIOgraph, Biopharmaceuticals, Clinical Diagnostics and Tools
The Bi-Partisan Cliff Deal Nobody Likes (Except the Market) Investors like the tax deal as it is favorable to investors despite the tax increases. Stocks are holding their gains after a “mini-fiscal” cliff deal that drove the Dow and S&P up 1.7% and...
by Raynovich Rod | Dec 24, 2012 | BIOgraph, Biopharmaceuticals
Outstanding Year for Biotechnology -Average Performance is up 35% YTD Many Rayno Life Science Stocks have outperformed the sector and the ETFs: Albany Molecular Inc. (AMRI), a contract research organization with long term experience in drug discovery, development and...
by Raynovich Rod | Nov 29, 2012 | BIOgraph, Biopharmaceuticals
Rayno Life Science Stocks Move Higher Biotech stocks are ignoring the volatility from the political fray today with big moves in many Rayno Life Science stocks and a 1.5% move in the bellwether ETF (IBB).The tech heavy QQQ lagged up only 0.7%. Overall, despite the...
by Raynovich Rod | Nov 20, 2012 | BIOgraph, Biopharmaceuticals, Clinical Diagnostics and Tools
Markets Are Back To Fretting About Fiscal Cliff Bernanke scolded Congress on the fiscal cliff and markets turned down. Despite a lackluster market down about 0.3% there is a lot of green in biotech. Among the winners in the Rayno Life Science universe are: Albany...
by Raynovich Rod | Nov 12, 2012 | BIOgraph, Biopharmaceuticals
A languishing biotech sector rallied today with clinical news with Hepatitis C (HCV) drugs. The Rayno Biopharma Portfolio was up 2.4% led by Gilead Sciences (GILD) up 11.5%, Regeneron (REGN) up 3.3% and ViroPharma (VPHM) up 3.2%. Gilead shares were up $7.50 on...
by Raynovich Rod | Nov 9, 2012 | BIOgraph, Biopharmaceuticals
Trends from early trading show promise for intermediate support in larger cap biotech shares today with the NASDAQ up 0.5% in early trading. This could be a good day for covering shorts and re-balancing in anticipation for a Q4 rally : The IBB (130.82) is up 1.88%....
by Raynovich Rod | Oct 31, 2012 | BIOgraph, Biopharmaceuticals
Huge Profits YTD Bring Selling-Momentum is Broken Profit taking has hit the biotechnology sector again today with major ETFs down 2% and momentum stocks hit harder. We recommended caution on 10/22 (see below) as momentum eased on stocks that were up over 100% YTD with...
by Raynovich Rod | Oct 22, 2012 | 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph
Biotech At Risk: Take a Little Off Speculative Stocks Biotechnology remains one of the strongest sectors of 2012 especially earnings driven, large cap stocks all doing well today: Amgen (AMGN $88.4) up 1%, Biogen (BIIB $142.6) up 0.4% and Gilead (GILD $68.85) up 6%....
by Raynovich Rod | Oct 11, 2012 | 2025 Rayno Biopharmaceuticals Portfolio, BIOgraph
Good Day for Biotech with a Strong Appetite for Two IPOs in A Choppy Market Intercept Pharmaceuticals (ICPT) was up 29.33% to $19.40 on a public offering of 5M shares at $15 raising $75M. The Company is developing clinical stage therapeutics to treat chronic liver...
